Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin.
1980; Lippincott Williams & Wilkins; Volume: 46; Issue: 5 Linguagem: Inglês
10.1161/01.res.46.5.625
ISSN1524-4571
AutoresJohn R. Guyton, R D Rosenberg, A W Clowes, M J Karnovsky,
Tópico(s)Protease and Inhibitor Mechanisms
ResumoHomeCirculation ResearchVol. 46, No. 5Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Free AccessAbstractPDF/EPUBAboutView PDFSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessAbstractPDF/EPUBInhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. J R Guyton, R D Rosenberg, A W Clowes and M J Karnovsky J R GuytonJ R Guyton , R D RosenbergR D Rosenberg , A W ClowesA W Clowes and M J KarnovskyM J Karnovsky Originally published1 May 1980https://doi.org/10.1161/01.RES.46.5.625Circulation Research. 1980;46:625–634 Previous Back to top Next FiguresReferencesRelatedDetailsCited By Aslani S, Kabiri M, HosseinZadeh S, Hanaee-Ahvaz H, Taherzadeh E and Soleimani M (2020) The applications of heparin in vascular tissue engineering, Microvascular Research, 10.1016/j.mvr.2020.104027, 131, (104027), Online publication date: 1-Sep-2020. Beurskens D, Huckriede J, Schrijver R, Hemker H, Reutelingsperger C and Nicolaes G (2020) The Anticoagulant and Nonanticoagulant Properties of Heparin, Thrombosis and Haemostasis, 10.1055/s-0040-1715460, 120:10, (1371-1383), Online publication date: 1-Oct-2020. Brewster L (2020) Back to the future but better, JVS-Vascular Science, 10.1016/j.jvssci.2020.04.002, 1, (68), . Wang L, Gong T, Brown Z, Gu Y, Teng K, Ye W and Ming W (2020) Preparation of Ascidian-Inspired Hydrogel Thin Films to Selectively Induce Vascular Endothelial Cell and Smooth Muscle Cell Growth, ACS Applied Bio Materials, 10.1021/acsabm.9b01190, 3:4, (2068-2077), Online publication date: 20-Apr-2020. McMonagle M (2020) The quest for effective pharmacological suppression of neointimal hyperplasia, Current Problems in Surgery, 10.1016/j.cpsurg.2020.100807, 57:8, (100807), Online publication date: 1-Aug-2020. Green D (2020) Non-anticoagulant heparins The Heparins, 10.1016/B978-0-12-818781-4.00002-9, (35-55), . Li P, Wang Y, Jin X, Dou J, Han X, Wan X, Yuan J and Shen J (2020) Catalytic Generation of Nitric Oxide from Poly(ε-caprolactone)/Phosphobetainized Keratin Mats for a Vascular Tissue Engineering Scaffold, Langmuir, 10.1021/acs.langmuir.0c00579, 36:16, (4396-4404), Online publication date: 28-Apr-2020. Chen Y, Zhao X and Liu Z (2018) Synthetic Hydrogels for Expansion of Functional Endothelial Cells Functional Hydrogels as Biomaterials, 10.1007/978-3-662-57511-6_2, (31-71), . Wan X, Wang Y, Jin X, Li P, Yuan J and Shen J (2018) Heparinized PCL/keratin mats for vascular tissue engineering scaffold with potential of catalytic nitric oxide generation, Journal of Biomaterials Science, Polymer Edition, 10.1080/09205063.2018.1504192, 29:14, (1785-1798), Online publication date: 22-Sep-2018. Zhang S, Jin L, Arshad M and Ullah A (2017) Renewable Biomaterials as Nanocarriers for Drug and Gene Delivery Drug and Gene Delivery to the Central Nervous System for Neuroprotection, 10.1007/978-3-319-57696-1_1, (1-32), . Kim J, Ko N, Jung B and Kwon I (2016) Development of a novel dual PLGA and alginate coated drug-eluting stent for enhanced blood compatibility, Macromolecular Research, 10.1007/s13233-016-4130-5, 24:10, (931-939), Online publication date: 1-Oct-2016. Mulloy B, Hogwood J, Gray E, Lever R, Page C and Sibley D (2015) Pharmacology of Heparin and Related Drugs, Pharmacological Reviews, 10.1124/pr.115.011247, 68:1, (76-141), Online publication date: 1-Jan-2016. Nakamura R, Nakamura F and Fukunaga S (2015) Perlecan Diversely Regulates the Migration and Proliferation of Distinct Cell Types in vitro, Cells Tissues Organs, 10.1159/000440950, 200:6, (374-393), . Liu T, Liu Y, Chen Y, Liu S, Maitz M, Wang X, Zhang K, Wang J, Wang Y, Chen J and Huang N (2014) Immobilization of heparin/poly-l-lysine nanoparticles on dopamine-coated surface to create a heparin density gradient for selective direction of platelet and vascular cells behavior, Acta Biomaterialia, 10.1016/j.actbio.2013.12.013, 10:5, (1940-1954), Online publication date: 1-May-2014. Liu T, Zeng Z, Liu Y, Wang J, Maitz M, Wang Y, Liu S, Chen J and Huang N (2014) Surface Modification with Dopamine and Heparin/Poly- l -Lysine Nanoparticles Provides a Favorable Release Behavior for the Healing of Vascular Stent Lesions , ACS Applied Materials & Interfaces, 10.1021/am5015309, 6:11, (8729-8743), Online publication date: 11-Jun-2014. Maurel B, Chai F, Maton M, Blanchemain N and Haulon S (2013) In stent restenosis and thrombosis assessment after EP224283 injection in a rat model, Atherosclerosis, 10.1016/j.atherosclerosis.2013.06.009, 229:2, (462-468), Online publication date: 1-Aug-2013. Page C (2013) Heparin and Related Drugs: Beyond Anticoagulant Activity, ISRN Pharmacology, 10.1155/2013/910743, 2013, (1-13), Online publication date: 30-Jul-2013. Lever R and Page C (2012) Non-anticoagulant Effects of Heparin: An Overview Heparin - A Century of Progress, 10.1007/978-3-642-23056-1_12, (281-305), . Yildiz A, John E, Özsoy Y, Araman A, Birchall J, Broadley K and Gumbleton M (2012) Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation, Journal of Controlled Release, 10.1016/j.jconrel.2012.07.008, 162:2, (456-463), Online publication date: 1-Sep-2012. Ma X, Wu T and Robich M (2012) Drug-eluting stent coatings, Interventional Cardiology, 10.2217/ica.11.88, 4:1, (73-83), Online publication date: 1-Feb-2012. Kirkwood M, Wang G, Jackson B, Golden M, Fairman R and Woo E (2011) Lower Limb Revascularization for PAD Using a Heparin-Coated PTFE Conduit, Vascular and Endovascular Surgery, 10.1177/1538574411401757, 45:4, (329-334), Online publication date: 1-May-2011. Garg H, Mrabat H, Yu L, Hales C, Li B, Moore C, Zhang F and Linhardt R (2011) Anti-proliferative effects of O-acyl-low-molecular-weight heparin derivatives on bovine pulmonary artery smooth muscle cells, Glycoconjugate Journal, 10.1007/s10719-011-9341-6, 28:6, (419-426), Online publication date: 1-Aug-2011. Krylov V, Ustyuzhanina N and Nifantiev N (2011) Synthesis of low-molecular-weight carbohydrate mimetics of heparin, Russian Journal of Bioorganic Chemistry, 10.1134/S1068162011060100, 37:6, (672-706), Online publication date: 1-Nov-2011. Adhikari N, Carlson M, Lerman B and Hall J (2011) Changes in Expression of Proteoglycan Core Proteins and Heparan Sulfate Enzymes in the Developing and Adult Murine Aorta, Journal of Cardiovascular Translational Research, 10.1007/s12265-011-9261-7, 4:3, (313-320), Online publication date: 1-Jun-2011. Baker A (2010) Role of Proteoglycans in Vascular Mechanotransduction Mechanosensitivity and Mechanotransduction, 10.1007/978-90-481-9881-8_9, (219-236), . Beamish J, He P, Kottke-Marchant K and Marchant R (2010) Molecular Regulation of Contractile Smooth Muscle Cell Phenotype: Implications for Vascular Tissue Engineering, Tissue Engineering Part B: Reviews, 10.1089/ten.teb.2009.0630, 16:5, (467-491), Online publication date: 1-Oct-2010. Song L, Xiao W and Templeton D (2010) Low-concentration heparin suppresses ionomycin-activated CAMK-II/EGF receptor- and ERK-mediated signaling in mesangial cells, Journal of Cellular Physiology, 10.1002/jcp.22147, 224:2, (484-490), Online publication date: 1-Aug-2010. Liao D, Wang X, Lin P, Yao Q and Chen C (2008) Covalent linkage of heparin provides a stable anti‐coagulation surface of decellularized porcine arteries, Journal of Cellular and Molecular Medicine, 10.1111/j.1582-4934.2008.00589.x, 13:8b, (2736-2743), Online publication date: 2-Aug-2009. Ceccarelli M, Bani D, Cinci L, Nistri S, Uliva C, Ragazzo E, Vannacci A, Manoni M, Gori A, Abbate R, Gensini G and Masini E (2009) Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy, Journal of Cellular and Molecular Medicine, 10.1111/j.1582-4934.2009.00658.x, 13:8b, (2704-2712), Online publication date: 1-Aug-2009. Ceccarelli M, Bani D, Cinci L, Nistri S, Uliva C, Ragazzo E, Vannacci A, Manoni M, Gori A, Abbate R, Gensini G and Masini E (2009) Anti‐inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan‐induced pleurisy, Journal of Cellular and Molecular Medicine, 10.1111/j.1582-4934.2008.00658.x, 13:8b, (2704-2712), Online publication date: 2-Aug-2009. Chen X, Xiao W, Qu X and Zhou S (2009) The Effect of Dalteparin, a Kind of Low Molecular Weight Heparin, on Lung Adenocarcinoma A549 Cell Line In Vitro , Cancer Investigation, 10.1080/07357900801935631, 26:7, (718-724), Online publication date: 1-Jan-2008. Kanabar V, Page C, Simcock D, Karner C, Mahn K, O'Connor B and Hirst S (2009) Heparin and structurally related polymers attenuate eotaxin-1 (CCL11) release from human airway smooth muscle, British Journal of Pharmacology, 10.1038/bjp.2008.109, 154:4, (833-842), Online publication date: 1-Jun-2008. Park K, Lee G, Park R, Kim I, Kim S and Byun Y (2007) Combination Therapy of Heparin–Deoxycholic Acid Conjugate and Doxorubicin against Squamous Cell Carcinoma and B16F10 Melanoma, Pharmaceutical Research, 10.1007/s11095-007-9366-5, 25:2, (268-276), Online publication date: 1-Feb-2008. Scharn D, Dirven M, Barendregt W, Boll A, Roelofs D and van der Vliet J (2008) Human Umbilical Vein versus Heparin-bonded Polyester for Femoro-popliteal Bypass: 5-year Results of a Prospective Randomized Multicentre Trial, European Journal of Vascular and Endovascular Surgery, 10.1016/j.ejvs.2007.08.004, 35:1, (61-67), Online publication date: 1-Jan-2008. Liu Y, Song L and Templeton D (2007) Heparin suppresses lipid raft-mediated signaling and ligand-independent EGF receptor activation, Journal of Cellular Physiology, 10.1002/jcp.20924, 211:1, (205-212), Online publication date: 1-Apr-2007. Park K, Lee G, Kim Y, Yu M, Park R, Kim I, Kim S and Byun Y (2006) Heparin–deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity, Journal of Controlled Release, 10.1016/j.jconrel.2006.05.017, 114:3, (300-306), Online publication date: 1-Sep-2006. GLAZIER J and SPEARS J (2005) Angiographic Observations 10 Years Following Coronary Laser Balloon Angioplasty, Journal of Interventional Cardiology, 10.1111/j.1540-8183.2005.00076.x, 18:5, (357-360), Online publication date: 1-Oct-2005. Gray M and Castellot J (2005) Regulation of smooth-muscle cell proliferation in leiomyomata Uterine Leiomyomas, 10.1201/b14628-5, (25-39), Online publication date: 8-Dec-2005. Varty K, Allen K, Bell P and London N (2005) Infrainguinal vein graft stenosis, British Journal of Surgery, 10.1002/bjs.1800800706, 80:7, (825-833), Online publication date: 8-Dec-2005. Kanabar V, Hirst S, O'Connor B and Page C (2009) Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle, British Journal of Pharmacology, 10.1038/sj.bjp.0706333, 146:3, (370-377), Online publication date: 1-Oct-2005. Wilson N, Kakkar V and Salisbury J (2005) Effect of low molecular weight heparin on intimal hyperplasia, British Journal of Surgery, 10.1002/bjs.1800781136, 78:11, (1381-1383), Online publication date: 8-Dec-2005. Aitsebaomo J, Moser M, Smyth S and Patterson C Coronary Restenosis Principles of Molecular Cardiology, 10.1007/978-1-59259-878-6_17, (291-308) Nugent M, Forsten-Williams K, Karnovsky M and Edelman E (2005) Mechanisms of Cell Growth Regulation by Heparin and Heparan Sulfate Chemistry and Biology of Heparin and Heparan Sulfate, 10.1016/B978-008044859-6/50020-4, (533-570), . Kannemeier C, Al‐Fakhri N, Preissner K and Kanse S (2004) Factor VII activating protease (FSAP) inhibits growth factor‐mediated cell proliferation and migration of vascular smooth muscle cells., The FASEB Journal, 10.1096/fj.03-0898fje, 18:6, (728-730), Online publication date: 1-Apr-2004. Lin P, Bush R, Yao Q, Lumsden A and Chen C (2004) Evaluation of platelet deposition and neointimal hyperplasia of heparin-coated small-caliber ePTFE grafts in a canine femoral artery bypass model1, Journal of Surgical Research, 10.1016/j.jss.2003.12.026, 118:1, (45-52), Online publication date: 1-May-2004. Dilley R, Rizkalla B and Bertram J (2004) Cardiovascular hypertrophy in one-kidney, one-clip renal hypertension is resistant to heparin, Journal of Hypertension, 10.1097/00004872-200404000-00020, 22:4, (767-774), Online publication date: 1-Apr-2004. Kavanagh C, Rochev Y, Gallagher W, Dawson K and Keenan A (2004) Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2003.01.001, 102:1, (1-15), Online publication date: 1-Apr-2004. Gori A, Attanasio M, Gazzini A, Rossi L, Lucarini L, Miletti S, Chini J, Manoni M, Abbate R and Gensini G (2004) Cytokine gene expression and production by human LPS-stimulated mononuclear cells are inhibited by sulfated heparin-like semi-synthetic derivatives, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2004.00866.x, 2:9, (1657-1662) Lin P, Chen C, Bush R, Yao Q, Lumsden A and Hanson S (2004) Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model, Journal of Vascular Surgery, 10.1016/j.jvs.2004.01.046, 39:6, (1322-1328), Online publication date: 1-Jun-2004. Lin P, Chronos N, Marijianowski M, Chen C, Bush R, Conklin B, Lumsden A and Hanson S (2003) Heparin-coated Balloon-expandable Stent Reduces Intimal Hyperplasia in the Iliac Artery in Baboons, Journal of Vascular and Interventional Radiology, 10.1097/01.RVI.0000071088.76348.23, 14:5, (603-611), Online publication date: 1-May-2003. Mason H, Nowak R, Morton C and Castellot J (2003) Heparin Inhibits the Motility and Proliferation of Human Myometrial and Leiomyoma Smooth Muscle Cells, The American Journal of Pathology, 10.1016/S0002-9440(10)64323-4, 162:6, (1895-1904), Online publication date: 1-Jun-2003. UNVERDORBEN M, SATTLER K, DEGENHARDT R, FRIES R, ABT B, WAGNER E, KOEHLER H, SCHOLZ M, IBRAHIM H, TEWS K, HENNEN B, DAEMGEN G, BERTHOLD H and VALLBRACHT C (2003) Comparison of a Silicon Carbide Coated Stent versus a Noncoated Stent in Humans:, The Journal of Interventional Cardiology, 10.1034/j.1600-6143.2003.08058.x, 16:4, (325-333), Online publication date: 1-Aug-2003. Liermann D and Kirchner J (2002) Kathetergestützte Rezidivprophylaxe Interventionelle Gefäßtherapie, 10.1007/978-3-642-57540-2_37, (420-426), . Garg H, Cindhuchao N, Quinn D, Hales C, Thanawiroon C, Capila I and Linhardt R (2002) Heparin oligosaccharide sequence and size essential for inhibition of pulmonary artery smooth muscle cell proliferation, Carbohydrate Research, 10.1016/S0008-6215(02)00190-8, 337:21-23, (2359-2364), Online publication date: 1-Nov-2002. Lovich M, Creel C, Hong K, Hwang C and Edelman E (2001) Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel, Journal of Pharmaceutical Sciences, 10.1002/jps.1085, 90:9, (1324-1335), Online publication date: 1-Sep-2001. Bingley J, Hayward I, Campbell G and Campbell J (2001) Relationship of glycosaminoglycan and matrix changes to vascular smooth muscle cell phenotype modulation in rabbit arteries after acute injury, Journal of Vascular Surgery, 10.1067/mva.2001.109774, 33:1, (155-164), Online publication date: 1-Jan-2001. BICKEL C, RUPPRECHT H, DARIUS H, BINZ C, HAURÖDER B, KRUMMENAUER F and MEYER J (2001) Substantial Reduction of Platelet Adhesion by Heparin-Coated Stents, Journal of Interventional Cardiology, 10.1111/j.1540-8183.2001.tb00350.x, 14:4, (407-413), Online publication date: 1-Aug-2001. Delmolino L, Stearns N and Castellot J (2001) COP-1, a member of the CCN family, is a heparin-induced growth arrest specific gene in vascular smooth muscle cells, Journal of Cellular Physiology, 10.1002/jcp.1100, 188:1, (45-55), Online publication date: 1-Jul-2001. Petty M and Wettstein J (2001) Elements of cerebral microvascular ischaemia, Brain Research Reviews, 10.1016/S0165-0173(01)00062-5, 36:1, (23-34), Online publication date: 1-Aug-2001. Berry D, Kwan C, Shriver Z, Venkataraman G and Sasisekharan R (2001) Distinct heparan sulfate glycosaminoglycans are responsible for mediating fibroblast growth factor‐2 biological activity through different fibroblast growth factor receptors, The FASEB Journal, 10.1096/fj.00-0661fje, 15:8, (1422-1424), Online publication date: 1-Jun-2001. Oesterle E, Bhave S and Coltrera M (2000) Basic fibroblast growth factor inhibits cell proliferation in cultured avian inner ear sensory epithelia, The Journal of Comparative Neurology, 10.1002/1096-9861(20000821)424:2 3.0.CO;2-M, 424:2, (307-326), Online publication date: 21-Aug-2000. Quartermain D, Li Y and Jonas S (2000) Enoxaparin, a low molecular weight heparin decreases infarct size and improves sensorimotor function in a rat model of focal cerebral ischemia, Neuroscience Letters, 10.1016/S0304-3940(00)01223-4, 288:2, (155-158), Online publication date: 1-Jul-2000. Ettenson D, Koo E, Januzzi J and Edelman E (2000) Endothelial heparan sulfate is necessary but not sufficient for control of vascular smooth muscle cell growth, Journal of Cellular Physiology, 10.1002/(SICI)1097-4652(200007)184:1 3.0.CO;2-H, 184:1, (93-100), Online publication date: 1-Jul-2000. Chen C, Lumsden A and Hanson S (2000) Local infusion of heparin reduces anastomotic neointimal hyperplasia in aortoiliac expanded polytetrafluoroethylene bypass grafts in baboons, Journal of Vascular Surgery, 10.1016/S0741-5214(00)90165-4, 31:2, (354-363), Online publication date: 1-Feb-2000. Garg H, Thompson B and Hales C (2000) Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells, American Journal of Physiology-Lung Cellular and Molecular Physiology, 10.1152/ajplung.2000.279.5.L779, 279:5, (L779-L789), Online publication date: 1-Nov-2000. Johnson M (2000) Percutaneous Periadventitial Heparin Delivery via Crosslinked Liquid Polymer, Journal of Vascular and Interventional Radiology, 10.1016/S1051-0443(00)70145-X, 11:2, (348-351), Online publication date: 1-Feb-2000. Logeart-Avramoglou D and Jozefonvicz J (1999) Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties: A review, Journal of Biomedical Materials Research, 10.1002/(SICI)1097-4636(1999)48:4 3.0.CO;2-8, 48:4, (578-590), . Kantor B, Ashai K, Holmes D and Schwartz R (1999) The experimental animal models for assessing treatment of restenosis, Cardiovascular Radiation Medicine, 10.1016/S1522-1865(98)00005-5, 1:1, (48-54), Online publication date: 1-Jan-1999. Garg H, Joseph P, Thompson B, Hales C, Toida T, Imanari T, Capila I and Linhardt R (1999) Effect of Fully Sulfated Glycosaminoglycans on Pulmonary Artery Smooth Muscle Cell Proliferation, Archives of Biochemistry and Biophysics, 10.1006/abbi.1999.1456, 371:2, (228-233), Online publication date: 1-Nov-1999. Teomim D, Fishbien I, Golomb G, Orloff L, Mayberg M and Domb A (1999) Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury, Journal of Controlled Release, 10.1016/S0168-3659(99)00071-1, 60:1, (129-142), Online publication date: 1-Jun-1999. Gimple L, Herrmann H, Winniford M and Mammen E (1999) Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty, The American Journal of Cardiology, 10.1016/S0002-9149(99)00141-1, 83:11, (1524-1529), Online publication date: 1-Jun-1999. Heinzelmann M, Miller M, Platz A, Gordon L, Herzig D and Polk H (1999) Heparin and Enoxaparin Enhance Endotoxin-Induced Tumor Necrosis Factor-α Production in Human Monocytes, Annals of Surgery, 10.1097/00000658-199904000-00014, 229:4, (542-550), Online publication date: 1-Apr-1999. Beythien C, Gutensohn K, Bau J, Hamm C, Kühnl P, Meinertz T and Terres W (1999) Influence of Stent Length and Heparin Coating on Platelet Activation, Thrombosis Research, 10.1016/S0049-3848(98)00198-4, 94:2, (79-86), Online publication date: 1-Apr-1999. Esente P, Kaplan A, Ford J, Martin J, Ayres M, Kosinski E, Lasorda D, Graham M, Gallant P, Grines L and Grines C (1999) Local intramural heparin delivery during primary angioplasty for myocardial infarction: Results of the local PAMI pilot study, Catheterization and Cardiovascular Interventions, 10.1002/(SICI)1522-726X(199906)47:2 3.0.CO;2-S, 47:2, (237-242), Online publication date: 1-Jun-1999. Schäfer U, Micke O, Dorszewski A, Breithardt G and Willich N (1998) External beam irradiation inhibits neointima hyperplasia after injury-induced arterial smooth muscle cell proliferation, International Journal of Radiation Oncology*Biology*Physics, 10.1016/S0360-3016(98)00249-1, 42:3, (617-622), Online publication date: 1-Oct-1998. Mestries P, Borchiellini C, Barbaud C, Duchesnay A, Escartin Q, Barritault D, Caruelle J and Kern P (1998) Chemically modified dextrans modulate expression of collagen phenotype by cultured smooth muscle cells in relation to the degree of carboxymethyl, benzylamide, and sulfation substitutions, Journal of Biomedical Materials Research, 10.1002/(SICI)1097-4636(199811)42:2 3.0.CO;2-H, 42:2, (286-294), Online publication date: 1-Nov-1998. Kohno M, Yokokawa K, Yasunari K, Minami M, Kano H, Mandal A and Yoshikawa J (1998) Heparin inhibits human coronary artery smooth muscle cell migration, Metabolism, 10.1016/S0026-0495(98)90279-7, 47:9, (1065-1069), Online publication date: 1-Sep-1998. Li P, He Q, Siddiqui M and Shuaib A (1998) Posttreatment with low molecular weight heparin reduces brain edema and infarct volume in rats subjected to thrombotic middle cerebral artery occlusion, Brain Research, 10.1016/S0006-8993(98)00559-9, 801:1-2, (220-223), Online publication date: 1-Aug-1998. Groudine S, Sakawi Y, Patel M, Darling C, Abdel-Raouf A, Paty P and Lumb P (1998) Low-dose heparin appears safe and can eliminate protamine use for carotid endarterectomy, Journal of Cardiothoracic and Vascular Anesthesia, 10.1016/S1053-0770(98)90009-X, 12:3, (295-298), Online publication date: 1-Jun-1998. OKADA K, BERNSTEIN M, ZHANG W, SCHUSTER D and BOTNEY M (1998) Angiotensin-converting Enzyme Inhibition Delays Pulmonary Vascular Neointimal Formation, American Journal of Respiratory and Critical Care Medicine, 10.1164/ajrccm.158.3.9710007, 158:3, (939-950), Online publication date: 1-Sep-1998. Wessel H (1997) Heparinoid mimetics Glycoscience Synthesis of Substrate Analogs and Mimetics, 10.1007/BFb0119258, (215-239), . San Antonio J, Verrecchio A and Pukac L (2009) Heparin Sensitive and Resistant Vascular Smooth Muscle Cells: Biology and Role in Restenosis, Connective Tissue Research, 10.3109/03008209809028903, 37:1-2, (87-103), Online publication date: 1-Jan-1998. Clairbois A, Letourneur D, Muller D and Jozefonvicz J (1998) High-performance affinity chromatography for the purification of heparin-binding proteins from detergent-solubilized smooth muscle cell membranes, Journal of Chromatography B: Biomedical Sciences and Applications, 10.1016/S0378-4347(97)00513-6, 706:1, (55-62), Online publication date: 1-Feb-1998. Liermann D, Kirchner J, Bauernsachs R, Schopohl B and Böttcher H (1998) Brachytherapy with iridium-192 HDR to prevent from restenosis in peripheral arteriesSieben Jahre Nachbeobachtung der Brachytherapie mit Iridium 192 zur Verhütung von Restenosen in peripheren Arterien-Eine Aktualisierung, Herz, 10.1007/BF03043605, 23:6, (394-400), Online publication date: 1-Sep-1998. Frishman W, Chiu R, Landzberg B and Weiss M (1998) Medical therapies for the prevention of restenosis after percutaneous coronary interventions, Current Problems in Cardiology, 10.1016/S0146-2806(98)80002-9, 23:10, (533-635), Online publication date: 1-Oct-1998. Castro A, Amorena C, Müller A, Ottaviano G, Tellez-Iñon M and Taquini A (1998) Extracellular ATP and bradykinin increase cGMP in vascular endothelial cells via activation of PKC, American Journal of Physiology-Cell Physiology, 10.1152/ajpcell.1998.275.1.C113, 275:1, (C113-C119), Online publication date: 1-Jul-1998. Mitchel J, Azrin M, Fram D, Bow L and McKay R (1997) Localized delivery of heparin to angioplasty sites with iontophoresis, Catheterization and Cardiovascular Diagnosis, 10.1002/(SICI)1097-0304(199707)41:3 3.0.CO;2-M, 41:3, (315-323), Online publication date: 1-Jul-1997. Fram D, Mitchel J, Azrin M, Chow M, Waters D and McKay R (1997) Local delivery of heparin to balloon angioplasty sites with a new angiotherapy catheter: Pharmacokinetics and effect on platelet deposition in the porcine model, Catheterization and Cardiovascular Diagnosis, 10.1002/(SICI)1097-0304(199707)41:3 3.0.CO;2-3, 41:3, (275-286), Online publication date: 1-Jul-1997. Simons M (1997) Endogenous Expression Modification: Antisense Approaches Gene Transfer in the Cardiovascular System, 10.1007/978-1-4615-6277-1_6, (143-175), . Han R, Ettenson D, Koo E and Edelman E (1997) Heparin/heparan sulfate chelation inhibits control of vascular repair by tissue-engineered endothelial cells, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.1997.273.6.H2586, 273:6, (H2586-H2595), Online publication date: 1-Dec-1997. Glazier J, Jiang A, Crilly R and Spears J (1997) Laser balloon angioplasty combined with local intracoronary heparin therapy: Immediate and short-term follow-up results, American Heart Journal, 10.1016/S0002-8703(97)70134-0, 134:2, (266-273), Online publication date: 1-Aug-1997. Lee S, Wang W, Joseph P, Hales C and Fanburg B (1997) Inhibitory Effect of Heparin on Serotonin-induced Hyperplasia and Hypertrophy of Smooth Muscle Cells, American Journal of Respiratory Cell and Molecular Biology, 10.1165/ajrcmb.17.1.2727, 17:1, (78-83), Online publication date: 1-Jul-1997. UENO H, MASUDA S, NISHIO S, LI J, YAMAMOTO H and TAKESHITA A (1997) Adenovirus-Mediated Transfer of Cyclin-dependent Kinase Inhibitor-p21 Suppresses Neointimal Formation in the Balloon-Injured Rat Carotid Arteries in Vivo, Annals of the New York Academy of Sciences, 10.1111/j.1749-6632.1997.tb52020.x, 811:1 Atheroscleros, (401-411), Online publication date: 1-Apr-1997. Ishibashi S, Ikeda U, Ihara T and Shimada K (1997) Tranilast inhibits contraction and Ca2+ movement of porcine coronary arteries, Atherosclerosis, 10.1016/S0021-9150(96)06053-4, 130:1-2, (113-119), Online publication date: 1-Apr-1997. McCarty M (1997) Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglycans, Medical Hypotheses, 10.1016/S0306-9877(97)90328-5, 48:3, (245-251), Online publication date: 1-Mar-1997. Guitteny A and Herbert J (1997) Failure of heparin to inhibit the expression of the thrombin receptor following endothelial injury of the rabbit carotid artery, European Journal of Pharmacology, 10.1016/S0014-2999(97)89655-0, 327:2-3, (157-162), Online publication date: 1-May-1997. MAK K and TOPOL E (1997) Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization, Annals of the New York Academy of Sciences, 10.1111/j.1749-6632.1997.tb52007.x, 811:1 Atheroscleros, (255-288), Online publication date: 1-Apr-1997. Pavlides G, Barath P, Maginas A, Vasilikos V, Cokkinos D and O'Neill W (1997) Intramural drug delivery by direct injection within the arterial wall: First clinical experience with a novel intracoronary delivery-infiltrator system, Catheterization and Cardiovascular Diagnosis, 10.1002/(SICI)1097-0304(199707)41:3 3.0.CO;2-2, 41:3, (287-292), Online publication date: 1-Jul-1997. Peter Wessel H, Iberg N, Trumtel M and Viaud M (1996) Selectively deoxygenated sulfated tetrasaccharides as probes for the investigation of smooth muscle cell antiproliferative activity, Bioorganic & Medicinal Chemistry Letters, 10.1016/0960-894X(95)00554-7, 6:1, (27-32), Online publication date: 1-Jan-1996. Preisack M and Karsch K (1996) Low molecular weight heparin in prevention of restenosis after PTCA, Thrombosis Research, 10.1016/0049-3848(95)00230-8, 81:2, (S53-S59), Online publication date: 1-Jan-1996. Karsch K, Preisack M, Baildon R, Eschenfelder V, Foley D, Garcia E, Kaltenbach M, Meisner C, Selbmann H, Serruys P, Shiu M, Sujatta M and Bonan R (1996) Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial), Journal of the American College of Cardiology, 10.1016/S0735-1097(96)00343-9, 28:6, (1437-1443), Online publication date: 1-Nov-1996. Sang Park J, Seung Nam Kim , Jong Man Won , Yong Bok Koh and In Chul Kim (2016) Synergistic Inhibitory Effect of Angiotensin-Converting Enzyme Inhibitor and Heparin on Intimal Hyperplasia After Rat Aorta Injury, Angiology, 10.1177/000331979604700102, 47:1, (9-14), Online publication date: 1-Jan-1996. Mehta D, Angelini G and Bryan A (1996) Experimental models of accelerated atherosclerosis syndromes, International Journal of Cardiology, 10.1016/0167-5273(96)02738-6, 56:3, (235-257), Online publication date: 1-Oct-1996. Chen C, Hughes J, Mattar S, Hanson S and Lumsden A (1996) Transgraft Infusion of Heparin to Prevent Early Thrombosis of Expanded PTFE Grafts in Canine Femoral Veins, Annals of Vascular Surgery, 10.1007/BF02000759, 10:2, (147-155), Online publication date: 1-Mar-1996. Wang A and Templeton D (1996) Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates, Kidney International,
Referência(s)